SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending due to rising concerns over increased competition from prediction markets and intensified regulatory scrutiny following the NCAA's call for federal action on college sports betting. While recent legal wins against prediction platforms offer a potential tailwind, community sentiment remains divided between those seeing a buying opportunity ahead of the Super Bowl and upcoming earnings, and others frustrated by the stock's recent performance.

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

Q/C Technologies Inc.

Q/C Technologies is trending as the appointment of Chelsea Voss from OpenAI to its Board of Directors reinforces the company's strategic pivot into advanced AI and quantum-class computing. The community is actively discussing the stock's low float and sees significant upside potential, fueled by this new leadership and the consulting role of Martin Shkreli. Many view QCLS as an undervalued legitimate quantum play poised for a substantial move despite past financial performance.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network Inc. is trending sharply higher due to news of a strategic AI licensing partnership in Africa, which includes an institution-approved mental health pilot program. The community is actively discussing a potential short squeeze, fueled by the stock's high short interest and low float, with many anticipating continued significant upward movement as it gets compared to other recent high-flying microcaps.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is generating significant discussion as investors keenly await upcoming 3-year functional results from its ELEVIDYS gene therapy's EMBARK Phase 3 trial. The community is buzzing with optimism for a potential positive outcome that could lead to a stock surge and even buyout speculation, though many are also voicing caution given the binary nature of such clinical readouts. This anticipated data for their Duchenne muscular dystrophy treatment is a major catalyst shaping sentiment around the company's valuation and future.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is a top trending stock following substantial insider share purchases by its CEO and a board member, signaling strong conviction. The community is buzzing with speculation about a potential short squeeze, fueled by perceived price manipulation and anticipation of further market-moving insights, including a rumored piece from Michael Burry. This confluence of events keeps GME at the forefront of investor discussion as it navigates key trading levels.

AABG Token

AABBG is trending as its community rallies behind a federal lawsuit against market makers, alleging securities fraud and pervasive market manipulation. Investors are anticipating a significant market revaluation, fueled by rising gold and silver prices, the development of new precious-metals-backed tokens, and the potential impact of its innovative rGO gold recovery technology.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Mannkind is actively discussed due to the highly anticipated FDA decision on Afrezza's dose conversion label update, with a significant portion of the community expecting positive news or a potential Black Box warning removal. This optimism is further fueled by reports of a record-setting quarter and upcoming regulatory milestones, setting the stage for a 'catalyst-rich year'. However, some investors express frustration over historical stock volatility and management, often drawing comparisons to the performance of peer companies.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following recent positive glioblastoma study data that indicates extended patient survival and immune recovery, which the community recognizes as a significant breakthrough despite initial headline misinterpretations. Investors are also keenly anticipating upcoming viral clearance data for HPV and progress on a papillary indication, fueling strong bullish sentiment against persistent short interest. The company's innovative manufacturing platform and global market expansions are seen as key long-term drivers for its potential to revolutionize cancer treatment.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust (SLV) is seeing a historic surge, fueled by strong industrial demand from emerging technologies like EVs and AI, coupled with a tight supply outlook including China's export restrictions. Community chatter highlights both euphoria over unprecedented gains and warnings of a parabolic blow-off top, as market participants debate the sustainability of this rally amidst broader discussions of dollar devaluation and a potential short squeeze.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is generating significant conversation, with investors eagerly awaiting clarity on promised new hyperscaler deals and upcoming earnings amidst frustration over its lagging performance compared to AI/HPC data center peers. Despite a recent positive zoning approval for its Cayuga site and its Google-backed Fluidstack partnership, the community is actively debating perceived management silence and persistent short seller influence, seeking a catalyst to drive momentum and decouple it from Bitcoin's price movements.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

RBC Capital⬆️the PT on $GHRS to $40 from $33, reiterated at Outperform and said, Raising Price Target to $40 Following Psychedelics Symposium and Reiterating Outperform 
$JNJ $HELP ATAI CYBN MNMD CMPS  
RBC Capital additionally said: 
Following our Psychedelics Symposium and discussions with mgmt., payers, and docs, we are increasingly optimistic on GHRS&#39;s long-term sales opportunity with GH001 and are raising our price target to $40 from $33 based on updated assumptions about drug pricing in-line with Spravato. 
With EoP2 meeting later this year and pivotal trials initiation on track for later this year, we believe that GHRS remains a high quality mid-stage story in the emerging psychedelics space.

TD Cowen reiterated $GHRS at a Buy rating  
$ATAI $JNJ $CMPS CYBN $MNMD  
Guggenheim reiterated GH Research PLC Buy/$29  
  
Here&#39;s what TD Cowen and Guggenheim had to say in their notes to investors: https://x.com/Quantumup1/status/2008227799920754816?s=20

TD Cowen reiterated $GHRS at a Buy rating$ATAI $JNJ CMPS CYBN MNMDGuggenheim reiterated GH Research PLC Buy/$29TD Cowen said ~Today's update was long anticipated as clinical safety and almost all preclinical safety, was very clean. We expect clinical respiratory safety and... https://t.co/szZ8TdrKjp

quantumup on X (formerly Twitter): "TD Cowen reiterated $GHRS at a Buy rating$ATAI $JNJ CMPS CYBN MNMDGuggenheim reiterated GH Research PLC Buy/$29TD Cowen said ~Today's update was long anticipated as clinical safety and almost all preclinical safety, ...

StockTwits Web

GH Research PLC

ATAI Life Sciences N.V.

Johnson & Johnson

COMPASS Pathways

Mind Medicine Inc - Ordinary Shares (Sub Voting)

Quantumup

Helus Pharma Inc.

 to $40 from $33, reiterated at Outperform and said, Raising Price Target to $40 Following Psychedelics Symposium and Reiterating Outperform 


 ATAI CYBN MNMD CMPS  
RBC Capital additionally said: 
Following our Psychedelics Symposium and discussions with mgmt., payers, and docs, we are increasingly optimistic on GHRS's long-term sales opportunity with GH001 and are raising our price target to $40 from $33 based on updated assumptions about drug pricing in-line with Spravato. 
With EoP2 meeting later this year and pivotal trials initiation on track for later this year, we believe that GHRS remains a high quality mid-stage story in the emerging psychedelics space.